Fig. 3From: BIOlogical Factors that Limit sustAined Remission in rhEumatoid arthritis (the BIO-FLARE study): protocol for a non-randomised longitudinal cohort studyParticipant journey through the study. If the DAS28-CRP ≥ 2.4 at the screening visit, the participant is referred back to their own rheumatology team, remaining on DMARDs. All remaining participants stop their DMARDs at day 0 and are followed up with routine visits, or patient requested ad-hoc visits for 24 weeks or until the point of flareBack to article page